bluebird bio (BLUE) AML Case is Unlikely Driven By Lentiglobin, Here's Why - Morgan Stanley

March 11, 2021 7:12 AM EST
Get Alerts BLUE Hot Sheet
Price: $30.48 +2.73%

Rating Summary:
    15 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 38 | Down: 18 | New: 7
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $45.00 price target on bluebird bio (NASDAQ: BLUE) after management provided an update indicating that it does not believe that Lentiglobin caused the AML case in the SCD trial for the following reasons:

1) Mgt. identified various mutations as well as key chromosomal abnormalities in this patient that have been associated with AML

2) Although Lentiglobin was found in the VAMP4 gene, the latter does not appear to be related with AML and
was not found to likely have impacted other genes in the vicinity or caused gene misregulation

The analyst stated "We agree with mgt. that lentiglobin does not appear to be the cause of the AML case and thus expect BLUE up on the news. That said, given unknowns around how regulators will view the case and what requirements they will have to resume the studies, some residual uncertainty remains."

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $33.15 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments

Related Entities

Morgan Stanley